Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive childhood cancer registry launches to unlock secrets of the disease

NCT ID NCT01117168

Knowledge-focused Sponsor: Children's Oncology Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is a large registry that collects information from children diagnosed with cancer across the US and Canada. Its goal is to help researchers understand patterns, causes, and characteristics of childhood cancer. No treatments or drugs are given—it is purely for research and future study planning.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this registry could help researchers better understand childhood cancer, leading to improved treatments or prevention strategies in the future.
What could go wrong
This is an observational registry, not a treatment trial. It collects data only and does not test any intervention, so direct benefits to participants are unlikely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

57,816 people

The number who actually took part.

Start date

Apr 2010

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Pediatric and adolescent patients diagnosed with cancer

Ages

Up to 21 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* All patients, diagnosed with a primary malignancy since the date the initial IRB approval was received for this study with any of the following diagnoses are eligible: * All cancer cases with an ICD-O histologic behavior code of two "2" (carcinoma in situ) or three "3" (malignant). * All lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant. * The benign/borderline conditions which will be reportable by agreement shall include: * Mesoblastic nephroma. * All teratomas, regardless of locations. * Myeloproliferative disease * Langerhans Cell histiocytosis * Patients with a secondary malignancy may be eligible provided they also meet the criteria in the above. These patients need to be enrolled using their primary diagnosis. * Participants 0 through 21 years of age are eligible; irrespective of eligibility for other COG studies. * Participant must be resident of the United States, Canada or Mexico.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain tumors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer brain neoplasm childhood malignant neoplasm Langerhans cell histiocytosis leukemia mesoblastic nephroma myeloproliferative neoplasm neoplasm sarcoma teratoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain tumors Leukemia Pediatric cancer Sarcoma

Contacts and locations

Locations

  • Children's Oncology Group

    Arcadia, California, 91006, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.